Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference

Rhea-AI Summary

Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the HC Wainwright Virtual BIOCONNECT Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 AM EST via the conference link. Exicure focuses on gene regulatory and immunotherapeutic drugs utilizing its proprietary Spherical Nucleic Acid (SNA™) technology. Currently, the company is developing candidates for Friedreich’s ataxia and has a drug in a Phase 1b/2 clinical trial for advanced solid tumors.

Positive

• Participation in HC Wainwright Virtual BIOCONNECT Conference enhances visibility.
• SNA technology presents unique advantages in targeting genetic disorders.
• Current preclinical and clinical development of drug candidates may lead to future growth.

Negative

• None.

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021.

The presentation will be available for on-demand viewing beginning January 11, 2021 at 6:00 AM EST via the virtual conference link: https://journey.ct.events/view/2c7ed6df-d98c-467b-a674-c4e7933e6ad7.

Replays of the presentation will be available on Exicure’s website for 90 days following the presentation.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.

For more information, visit Exicure’s website at www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201229005040/en/

FAQ

What will David Giljohann present at the HC Wainwright Virtual BIOCONNECT Conference?

David Giljohann will present information about Exicure's gene therapy developments and its proprietary Spherical Nucleic Acid technology.

When is the HC Wainwright Virtual BIOCONNECT Conference?

The conference will be held from January 11 to January 14, 2021.

What is the significance of Exicure's Spherical Nucleic Acid technology?

Exicure's SNA technology offers unique chemical and biological properties that may provide therapeutic advantages over traditional nucleic acid therapies.

What clinical trials are currently ongoing for Exicure?

Exicure's drug candidate AST-008 is in a Phase 1b/2 clinical trial for patients with advanced solid tumors.

Where can I find the presentation after the conference?

Replays of the presentation will be available on Exicure’s website for 90 days following the conference.